Frequency Therapeutics, Inc.

In July 2019, Frequency Therapeutics, Inc. announced the closing of a $62 million Series C round financing. The Company is focused on developing small molecules to activate progenitor cells in the body to restore healthy tissues.

Proceeds will be used to further support the Company’s Progenitor Cell Activation (PCA) technology. Frequency’s lead compound, FX-322, activates the regrowth of sensory cells in the inner ear to treat chronic noise induced hearing loss.